Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05148780 · ClinicalTrials.gov registry record · Early Phase 1
A Study of Acute Respiratory Infections in Global Outpatient Setting
A Early Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 245
- Enrollment target
NCT05148780 is a Early Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 245 participants.
The verdict
NCT05148780, a Early Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 245 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the positivity rate of respiratory syncytial virus (RSV), influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in high-risk participants presenting with acute respiratory infections (ARIs) in outpatient settings during the influenza/RSV season and to evaluate the association between lower respiratory tract disease (LRTD) and ARI-related hospitalization in participants positive for RSV.
Interventions
- DIAGNOSTIC_TEST Nasal Swab Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2023-02-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05148780
The ClinicalTrials.gov registry entry for NCT05148780 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nasal Swab Sample is the first listed.
NCT05148780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05148780 about?
NCT05148780 is a clinical study titled "A Study of Acute Respiratory Infections in Global Outpatient Setting". The purpose of this study is to evaluate the positivity rate of respiratory syncytial virus (RSV), influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in high-risk participants presenting with acute respiratory infections (ARIs) in outpatient settings during the influenz...
What is the current status of trial NCT05148780?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 245 participants. The study started on 2021-12-20. Estimated completion is 2023-02-22.
What interventions are being tested in trial NCT05148780?
The interventions under investigation include: Nasal Swab Sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05148780?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.